This post is not from the Dechert side of the blog.
We previously noted that California’s expert admissibility standard, under Sargon Enters., Inc. v. Univ. of S. Cal., 55 Cal. 4th 747 (2012), is pretty darn close to the new federal standard under amended Rule 702. Although we know that standard ought to result in legitimate gatekeeping that thwarts junk science, we sometimes read California expert opinions with bated breath. Today’s decision, In re Ranitidine Cases, 2026 WL 3212637, at *1 (Cal. Super. Ct. Nov. 6, 2026), gave us a big sigh of relief. The court scrupulously applied the expert admissibility standard under Sargon and refused to allow the testimony of two specific causation experts.
The decision involves the long-running Zantac litigation. The MDL court effectively ended the majority of the federal litigation when it excluded plaintiffs’ causation experts under Rule 702, and the Delaware Supreme Court soon followed suit (see here and here). Now, California has joined the “keep junk science out of the courtroom party” and shut down plaintiffs’ specific causation experts in the initial California bellwether cases.
Both of plaintiffs’ specific causation experts offered opinions that the plaintiffs, by taking ranitidine, were exposed to levels of an alleged toxin (NDMA) at levels sufficient to have caused plaintiffs’ colon and prostate cancers. Plaintiffs’ first expert did not make any estimate of the amount of exposure to NDMA, and the expert did not know and could not estimate how much NDMA was in the pills that the plaintiffs used. Instead, he “assumed that whatever undefined amount was in the ranitidine was an unsafe amount because the FDA recalled the drugs and other litigation experts found general causation.” Id. at *4. Indeed, the expert testified that, based solely on the fact that a plaintiff “took” ranitidine, he would offer the same dosage-free opinion about anyone who took the medicine. Id. at *5. That testimony stood in stark contrast to the expert’s testimony that the FDA’s acceptable daily intake threshold for NDMA is not a causation threshold, and that the FDA has never determined that ingestion of an amount of NDMA above the FDA’s threshold will cause colon cancer.
Given these flaws in the expert’s methodology, the court held that the expert “lacked a sufficient factual basis for his opinion that NDMA in ranitidine was a substantial contributing factor in causing [plaintiffs] to develop colon cancer.” Id. The expert (1) had no information about the amount of NDMA in the medicine, (2) did not rely on data “of a type that reasonably may be relied upon by an expert,” (3) had no “sound logic” for his opinion that some unknown amount of NDMA caused a “non-trivial elevation in cancer risk that in turn was a substantial factor in causing the cancer,” and (4) did not calculate what exposure the plaintiffs may have had to NDMA and offered no logical reason why that unknown exposure created an increased risk of cancer. Id.
Plaintiffs’ second specific causation expert went a little further, in that he purported to determine the amount of NDMA in ranitidine. But most of the data he relied on involved expired pills, and there is evidence that the active ingredient in ranitidine degrades into NDMA over time. But importantly, there was no evidence that the plaintiffs ingested expired pills. Beyond that, the expert picked some studies but ignored others (including the FDA’s study) in developing his opinion about plaintiffs’ potential NDMA exposure. The court found that to be a “classic arbitrary ‘cherry picking’ exercise.” Id. at *7. The expert also relied on animal and non-pharmaceutical studies that were not specific to plaintiffs’ alleged cancers, and he attempted to extrapolate exposure information from a study involving airborne exposure rather than oral pill consumption.
Given those unreliable methodologies, the court had no problem excluding the expert’s opinions. Each step in the expert’s process of developing his opinion was unreliable:
- The expert “inexplicably” did not consider the FDA’s testing data, even though he admitted that he did not disagree with “the accuracy or validity of the FDA’s results.”
- He relied on testing of expired pills even though there was no information that the plaintiffs took expired pills.
- He relied on a study that specifically stated it did not study colon cancer to develop an opinion that the ingestion of ranitidine caused colon cancer.
- His reliance on an airborne exposure study in the context of an opinion about orally ingested pills was not based on “sound logic.”
Id. at *8. Quoting from a Florida opinion that excluded the same expert, the court summed up its holding as follows: “The steps [the expert] has taken to reach this opinion are not a part of any reliable methodology, let alone a reliable application of any methodology . . . . [The expert] layers a novel extrapolation on top of [the airborne exposure study] based on pure guesswork.” Id., quoting Wilson v. Boehringer Ingelheim Pharmaceuticals, Inc., 2024 WL 4007445 (Fla. Cir. Ct. Aug. 15, 2024).
So, California, we welcome you to the Zantac “keep junk science out of the courtroom party.” We’ll put another mark in the “win” column both for the proper application of expert admissibility standards and for the defendants in the Zantac litigation.
